Use of antihypertensive and lipid-lowering drugs: The management of cardiovascular risk in clinical practice

Journal of Human Hypertension

Volumn 21, Issue 1, 2007, Pages 53-59

  Di Martino, M ^a   Esposti, L Degli ^b   Filigheddu, F ^c   Veronesi, C ^d   Salerno, G ^e   Saragoni, S ^d   Glorioso, N ^c   Didoni, G ^f   Esposti, E Degli ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d Economics and Outcomes Research   (Italy)

^e General Practice   (Italy)

^f DuPont Italia Srl   (Italy)

^g Local Health Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRACTICE GUIDELINE; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK MANAGEMENT;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33845528935     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002102     Document Type: Article

References (28)

1. Lander ES, Schork NJ. Genetic dissection of complex trait. Science 1994; 265: 2037-2048.
2. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis, and Management, 2nd edn, Raven Press: New York, 1995, pp. 67-88.
3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII). JAMA 2003; 289: 2560-2572.
4. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-1610.
5. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee. J Hypertens 2003; 21: 1011-1053.
6. Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood pressure control in the hypertensive population. Lancet 1997; 349: 454-457.
7. Primatesta P, Poulter NR. Improvement in hypertension management in England: Results from the Health Survey for England 2003. J Hypertens 2006; 24: 1187-1192.
8. Muntner P, DeSalvo KB, Wildman RP, Raggi P, He J, Whelton PK. Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiol 2006; 163: 913-920.
9. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, et al., InterASIA Collaborative Group. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation 2004; 110: 405-411.
10. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: Findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation 2003; 107: 2185-2189.
11. Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: Results from the Health Survey for England 2003. Clin Endocrinol (Oxford) 2006; 64: 292-298.
12. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
13. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 1997; 30: 968-974.
14. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77: 37-40.
15. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-2524.
16. Goode GK, Miller JP, Heagerty AM. Hyperlipidemia, hypertension and coronary heart disease. Lancet 1995; 345: 362-364.
17. Wierzbicki AS. Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 2002; 16: 753-760.
18. Glorioso N, Troffa C, Filigheddu F, Dettori F, Soro A, Parpaglia PP et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-1286.
19. Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Circulation 2004; 110(Suppl III): III-402 (abstract 1905).
20. Wierzbicki AS. Statins and hypertension. J Hum Hypertens 2006; 20: 554-556.
21. Nawarskas JJ, Spinler SA. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy 1998; 18: 1041-1052.
22. Degli Esposti E, Sturani A, Di Martino M, Falasca P, Novi MV, Baio G et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439-444.
23. Degli Esposti E, Berto P, Buda S, Di Nardo AM, Sturani A. The Pandora project: Results of the pilot study. Am J Hypertens 1999; 12: 790-796.
24. Guidelines for ATC classification and DDD assignment, 5th edn, WHO Collaborating Centre for Drug Statistics Methodology: Oslo, 2002.
25. Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: A real practice analysis in Italy. Eur J Clin Pharmacol 2005; 61: 225-230.
26. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021-1023.
27. Camisasca P, Avanzini F, Alli C, Colombo F, Tognoni G. Overall cardiovascular risk still ignored in general practice care of hypertension. J Cardiovasc Risk 2002; 9: 147-152.
28. Tragni E, Catapano AL, Bertelli A, Poli A. Achievement of the therapeutic goals for dyslipidemia in clinical practice: Results of a survey among general practice physicians from Lombardy. Ital Heart J 2003; 4(Suppl 7): 47S-57S.